Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc.
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22 nd Annual Craig-Hallum Institutional Investor Conference
LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner . The Top Workplaces program has an 18-year history of surveying and celebrating people-first
Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025 ; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m.
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13.
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc.
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD